"Early diagnosis of Alzheimer's Disease is critical for patients and their families to receive the most beneficial treatment and medications," says lead researcher D.P. Devanand, MD, Professor of Clinical Psychiatry and Neurology at Columbia University and Co-Director of the Memory Disorders Center at the New York State Psychiatric Institute. "While currently there is no cure for the disease, early diagnosis and treatment can help patients and their families to better plan their lives."
Smell identification test results from Alzheimer's disease patients, MMCI patients and healthy elderly subjects were analyzed to select an optimal subset of fragrances that distinguished Alzheimer's and MMCI patients who developed the disease from healthy subjects and MMCI patients who did not develop Alzheimer's. Results of the 10-smell test, which can be administered in five to eight minutes, were analyzed in Dr. Devanand's study which evaluated 150 patients with MMCI every six months and 63 healthy elderly subjects annually, with average follow-up duration of five years. Inability to identify 10 specific odors (derived from the broader study) proved to be the best predictors for Alzheimer's Disease: strawberry, smoke, soap, menthol, clove, pineapple, natural gas, lilac, lemon and leather.
"Narrowing the list of odors can potentially expedite screening and help with early diagnosis," says Dr. Devanand, who added that pathological studies of brains of patients with Alzheimer's disease show that the nerve pathways involved in perceiving and recognizing odors are affected at a very early stage.
The research, funded by the National Institute on Aging, also focuses on brain imaging tests and performance on memory and other cognitive tests, and is expected to help physicians determine the most effective combination of tests to diagnose Alzheimer's disease.
An estimated 4.5 million Americans have Alzheimer's Disease, a progressive brain disorder that gradually destroys a person's memory. The number of Americans with the disease has more than doubled since 1980.
ACNP, founded in 1961, is a professional organization of more than 700 leading scientists, including four Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances.
Jill Lobliner 202-745-5114; Brian Ruberry 202-745-5113.